Bevacizumab prolongs survival in advanced cervical cancer, UC Irvine-led trial finds
Orange, Calif., Feb. 20, 2014 — Women with advanced cervical cancer now have a new treatment option that could lengthen their lives. A trial led by UC Irvine gynecologic oncologist Dr. Krishnansu S. Tewari found that combining chemotherapy with bevacizumab, also known as Avastin, extended median survival to 17 months, compared to 13.3 months for those receiving chemotherapy […]